Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin

Internal Medicine

Volumn 53, Issue 6, 2014, Pages 571-575

  Furuta, Takahisa ^a   Sugimoto, Mitsushige ^a   Yamade, Mihoko ^a   Uotani, Takahiro ^a   Sahara, Shu ^a   Ichikawa, Hitomi ^a   Kagami, Takuma ^a   Yamada, Takanori ^a   Osawa, Satoshi ^a   Sugimoto, Ken ^a   Watanabe, Hiroshi ^a   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

H. pylori; Metronidazole; Penicillin allergy; Sitafloxacin

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SITAFLOXACIN; ANTIINFECTIVE AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DIARRHEA; FEMALE; HELICOBACTER INFECTION; HUMAN; LOOSE FECES; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN ALLERGY; RETROSPECTIVE STUDY; UREA BREATH TEST; BREATH ANALYSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG HYPERSENSITIVITY; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOLOGY; JAPAN; METABOLISM; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BREATH TESTS; CYTOCHROME P-450 CYP2C19; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; METRONIDAZOLE; MIDDLE AGED; PENICILLINS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896303132     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1677     Document Type: Article

References (20)

1. Malfertheiner P. Guidelines for the diagnosis and treatment of H. pylori infection. MMW Fortschr Med 145: 42-45, 2003.
2. Muranaka M, Kabe J, Umezono K, et al. Incidence of drug hypersensitivity. Jpn J Allergol 13: 431-434, 1964 (in Japanese, Abstract in English).
3. Muranaka M, Okumura H, Takeda K, et al. Population studies on drug hypersensitivities. Acta Allergol 28: 50-61, 1973.
4. Harris AW, Pryce DI, Gabe SM, et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 10: 1005-1008, 1996.
5. Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45: 68-76, 2000.
6. Watanabe K, Tanaka A, Imase K, et al. Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003. Helicobacter 10: 4-11, 2005.
7. Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 21: 262-267, 2006.
8. Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother 53: 3097-3099, 2009.
9. Karczewska E, Klesiewicz K, Skiba I, et al. Variability in prevalence of Helicobacter pylori strains resistant to clarithromycin and levofloxacin in southern Poland. Gastroenterol Res Pract 2012: 418010, 2012.
10. Bogaerts P, Berhin C, Nizet H, et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11: 441-445, 2006.
11. Furuta T, Soya Y, Sugimoto M, et al. Rapid automated genotyping of CYP2C19 and Helicobacter pylori 23S rRNA gene in gastric juice. Gastroenterol Hepatol Res 2: 508-512, 2013.
12. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39: 1001-1005, 2007.
13. Yamade M, Sugimoto M, Uotani T, et al. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 26: 1457-1461, 2011.
14. Hirata Y, Ohmae T, Yanai A, et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 39: 352-355, 2012.
15. Furuta T, Sugimoto M, Uotani T, et al. Present status and future prospects of third line rescue regimens for H. pylori infection. Nihon Rinsho 71: 1404-1412, 2013 (in Japanese).
16. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 42: 287-290, 2010.
17. Gisbert JP, Gisbert JL, Marcos S, et al. Helicobacter pylori firstline treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 22: 1041-1046, 2005.
18. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 1: 121-128, 2002.
19. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first-and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 50: 634-639, 2005.
20. Furuta T, Sugimoto M, Shirai N, et al. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 8: 1199-1210, 2007.